within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CA07_Epicillin;
model Epicillin 
   extends Pharmacolibrary.Drugs.ATC.J.J01CA07;

  annotation(Documentation(
    info ="<html><body><p>Epicillin is a beta-lactam antibiotic belonging to the aminopenicillin class, structurally related to ampicillin. It was previously used for bacterial infections sensitive to aminopenicillins. However, it is currently not approved or marketed for clinical use in most countries due to the availability of better alternatives and limited clinical adoption.</p><h4>Pharmacokinetics</h4><p>No published studies with detailed pharmacokinetic parameters for epicillin in humans were found. Thus, the following estimates are based on known properties of structurally related aminopenicillins (such as ampicillin) and assumptions appropriate for a typical adult population with normal renal function.</p><h4>References</h4><ol><li><p>Nau, H (1987). Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. <i>Developmental pharmacology and therapeutics</i> 10(3) 174–198. DOI:<a href=&quot;https://doi.org/10.1159/000457744&quot;>10.1159/000457744</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3301235/&quot;>https://pubmed.ncbi.nlm.nih.gov/3301235</a></p></li><li><p>Guggenbichler, JP, et al., &amp; Rohrer, R (1981). [Pharmacokinetic of antibiotics in patients with mucoviscidosis (author&#x27;s transl)]. <i>Padiatrie und Padologie</i> 16(4) 393–402. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7301388/&quot;>https://pubmed.ncbi.nlm.nih.gov/7301388</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Epicillin;
